BUZZ-Zevra Therapeutics rises on agreement to sell its FDA priority review voucher for $150 mln

Shares of Zevra Therapeutics ZVRA.O rise 5.14% to $7.77

Zevra says it enters agreement to sell its rare pediatric disease Priority Review Voucher (PRV) for $150 million

The U.S. FDA granted the company PRV in September 2024 after approval of its drug Miplyffa

Miplyffa is indicated for use in combination with co's other genetic disorder drug, miglustat, to treat rare neurological condition passed genetically in adult and pediatric patients 2 years of age and older

PRV holders can benefit from an expedited six-month review of a new drug application for any disease by the FDA

ZVRA has fallen 7.19% YTD